Patient P-01496

Synthetic patientNBL-101 · Day 108 · 25–34 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Improving

GI state

Stable

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

70%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 51 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 53 SC-12 recommended — Supportive Compound SC-12
Day 54 Patient accepted — Started SC-12 in the companion
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 60 GI symptom burden −17% vs expected — Supportive Compound SC-12
Day 61 Patient accepted — Started GI-04 in the companion
Day 66 Tolerance state changed — Unstable → Improving
Day 69 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 51.

Primary contributors, last 14 days

Toxicity-8
Inflammatory activity-5
GI instability-4
Nutritional resilience+3
Treatment adherence-2

What helped?

Supportive Compound SC-12Day 53
Result: symptom burden −17%
GI Support Protocol GI-04Day 60
Result: no meaningful change

LIFE OS recommendation

Dietary Support Protocol NP-02

55%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

56.4/100

worsening · +3.3 vs previous 14 d

Toxicity

Blood

48.6/100

stable · +0.0 vs previous 14 d

Sleep quality

Wearable

41.5/100

worsening · -2.5 vs previous 14 d

Energy level

Daily log

3.2/10

worsening · -0.3 vs previous 14 d

Stress level

Daily log

7.6/10

stable · +0.1 vs previous 14 d

Steps

Wearable

4,613

worsening · -337 vs previous 14 d

Adherence

Companion

48.6 %

stable · -0.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 27 from the failing basin, 61 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 77 similar · onset 3 d · confidence 66%
NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 66%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 66%

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep histamine low
GI +5.6 next day on high-intake days · n 20
Keep alcohol low
GI +4.9 next day on high-intake days · n 16

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+5.6detractor · 95%
Alcohol
+4.9detractor · 95%
Spicy / capsaicin
+2.6no signal · 50%
Insoluble fibre
-1.1no signal · 22%
Simple carbohydrates
-0.8no signal · 16%
Dietary fat load
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 58
- WearableHRV 26 ms, trending down
Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 49
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 3.1 · butyrate capacity 48/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 24 ms
Sleep: 6.5 h
Steps: 4,409
Resting HR: 71 bpm

Daily log: GI score 56, nutritional resilience 39, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	22%	S19	AD-05	improved	61
P-01696	32%	S20	CR-01	improved	59
P-01371	31%	S06	CR-01	improved	63
P-01708	31%	S07	CR-01	improved	59
P-01388	30%	S17	CR-01	improved	59
P-01835	30%	S17	CR-01	improved	56
P-01442	29%	S13	CR-01	improved	61
P-01877	28%	S01	CR-01	improved	67
P-01430	22%	S05	CR-01	improved	54
P-01342	21%	S11	DT-01	improved	48
P-01393	60%	S14	GI-04	improved	53
P-01339	57%	S14	GI-04	improved	54